Home/Case studies/forecastVUE
Case study · forecastVUE · What to build
Preference said 8%. The forecast said 2%, and the client chose to exit.
A global medical device company needed to decide whether a new product roadmap was worth the investment.
Global medical device company
The product and marketing team
Whether a new product roadmap was worth the investment
Before committing to a multi-year launch plan
The challenge
A crowded category, loyal patients, and a roadmap that needed numbers.
The company competed in a home-use device category where patients replace their device only every few years and many never change brands. It had a roadmap: a next-generation device, then a second, smaller form factor, then a monitoring feature added to both.
The team needed to know what each step was worth, in share and in units, year by year, so it could set plans and investment. A simple preference survey would have overstated the answer, because most patients cannot or will not switch in any given year.
What we did
Measured choice, then built in the real-world limits on switching.
Current users, people considering the therapy and parents of child patients chose between realistic devices that varied brand, form factor, screen, remote, software and monitoring. For each year we set up the competitive set patients would actually face. The preference shares were then adjusted for the share of patients unwilling to switch brands, the share able to replace a device in a given year, and the share of clinicians who present the brand. Combined with the client's market model, that produced units and share by year, by scenario. A senior Quest professional built the model and the recommendation.
Method. forecastVUE share and volume forecast. More than 500 patients and caregivers across three user groups. Choice exercise on seven device features. A competitive scenario for each year. Adjustments for brand loyalty, replacement cycles and clinician access. Online.
The decision
A small realistic start, and a low ceiling even with every launch.
Stated preference looked promising. Once replacement cycles, brand loyalty and limited clinician access were built in, the realistic first-year share was 2.2%.
Two levers moved the forecast. Clinician access was the biggest: volume rose almost one for one with access. The second form factor was the roadmap step that mattered, adding about a point of share in its launch year, with its strongest appeal among patients using a competitor's similar device. Even with the full roadmap and access rising to the client's planning estimate, share stayed small by year six.
The result
The client chose to exit the business.
After the forecast, the client decided to exit the business, as reported by the client. The model had given the team what a preference survey could not: a realistic view of the share and units each step of the roadmap would earn, and of how much depended on access the company did not control.
What they walked away with
An answer the team could act on.
- Share and units for each year and each roadmap scenario
- The gap between stated preference and realistic share, explained step by step
- The value of clinician access, in units
- A model the team could rerun as the market changed
Client details withheld at the client's request. Result as reported by the client. Forecast figures are study estimates, not in-market results.